Epistemis

Dexamethasone, Ondansetron and Droperidol

  • Prophylaxis and Treatment of PONV

Postoperative nausea and vomiting (PONV) represent one of the most common and bothersome postsurgical complications, requiring a systematic and multimodal preventive approach guided by predictive risk scales.

Mechanism

Synergistic Mechanism of Combined Prophylaxis

The combined use of two or more antiemetics with different molecular targets of action offers a synergistic therapeutic effect superior to increasing the dose of a single compound:

  • Ondansetron: Selective antagonist of the serotonin 5-HT3 receptor, blocking gastric afferent vagal transmission to the bulbar postrema area.
  • Dexamethasone: High-potency corticosteroid that exerts a powerful central preventive effect at the cellular level, reducing the synthesis of inflammatory prostaglandins and attenuating systemic inflammation that stimulates the vomiting center.
  • Droperidol: Butyrophenone that acts as a potent and selective antagonist of central dopamine type D2 receptors located in the gastric chemoreceptor trigger zone.

Indicators and dose

Optimal Dosage and Administration Times

Drug Standard Adult Dose Adm. Route Optimal Timing of Administration
Dexamethasone 4 - 8 mg Intravenous At the time of anesthetic induction (requires prolonged cellular latency to manifest its genomic anti-inflammatory effect)
Ondansetron 4 mg Intravenous / Oral At the end of the surgical procedure (approximately 20-30 minutes before the patient wakes up)
Droperidol 0.625 - 1.25 mg Intravenous At the end of the procedure or with induction

Security

Risk factors and Apfel Scale

Prophylactic clinical decision-making is governed by the simplified Apfel predictive scale, which associates a cumulative value with four independent clinical risk factors:

  1. Female sex.
  2. Personal history of PONV or severe motion sickness (traveler's motion sickness).
  3. Active non-smoking status.
  4. Postoperative use of systemic opioid analgesics.

The presence of 1, 2, 3 or 4 of these factors predicts a risk of suffering PONV of 20%, 40%, 60% and 80%, respectively, requiring the mandatory establishment of preventive multimodal pharmacological prophylactic guidelines.

Class Contraindications

  • Ondansetron and Droperidol: Congenital long QT syndrome or pre-existing acquired prolongation of the QTc interval. Both compounds can alter myocardial repolarization by dose-dependently blocking hERG rectifying potassium channels, requiring prior electrocardiographic control if basal arrhythmias are suspected.
  • Dexamethasone: Patients with severe, metabolically uncontrolled diabetes mellitus (it can induce acute peaks of refractory perioperative hyperglycemia that are difficult to control and impair healing).

Epistemis is educational review material. It is not a medical device, does not diagnose or prescribe treatment, and does not replace formal medical training, current clinical guidelines, or professional clinical judgment.

System
Anesthesiology
Cluster
Prophylaxis and Treatment of PONV
Download Epistemis